was a biopharmaceutical company headquartered in cambridge massachusetts the company was focused on discovering and developing new therapies designed to treat patients by reprogramming the immune system allowing for long term remission of immune related diseases after a short course of therapy targeted diseases include type 1 diabetes rheumatoid arthritis inflammatory bowel disease ibd cancer chronic and viral diseases in 2008 tolerx was named one of fierce biotech s fierce 15 in october 2011 tolerx was shut down due to an unsuccessful phase iii trial in patients recently diagnosed with type 1 diabetes tolerx s lead product candidate otelixizumab also known as trx4 is a novel monoclonal antibody being developed for the treatment of autoimmune type 1 diabetes and other autoimmune diseases the efficacy and safety of otelixizumab in the treatment of type 1 diabetes is currently being studied in a pivotal phase 3 study called defend durable response therapy evaluation for early or new onset type 1 diabetes tolerx entered into a collaboration with glaxo smithkline in october 2007 relating to the development and commercialization of otelixizumab otelixizumab has been granted orphan drug status by the u s food and drug administration additionally in collaboration with genentech tolerx is